Elsevier 2020-2024

No publishing costs for Dutch authors in more than 2200 'hybrid' and full open access journals.

Publisher
Elsevier
Deal duration
2020-2024
2016
358
2017
795
2018
978
2019
1428
2020
4462
2021
4231
Status licence
Current

 

License and conditions

  • All accepted articles by corresponding authors of Dutch universities ( including University Medical Centres), NWO and the KNAW in the selected journals by Elsevier are eligible for open access publication without extra cost.
  • Publication types that are part of the agreement: Full Length Article, Review Article, Short Communication, Case Report, Data, Micro-article, Original Software Publication, Practical Guideline, Protocol, Replication Study, Short Survey, Video. Other publication types as Letters, Editiorals and Discussions are currently NOT part of the agreement but can instead be made freely available under 'promotional access' on request by the author(s) by contacting agreementactivation@elsevier.com.
  • N.B. New journals are included in the agreement several times. The APC discount conditions only apply to these journals if articles are submitted after date of inclusion. Search for a journal in the Open Access Journal Browser to see after which date an article must have been submitted to be eligible for a full APC discount.

How does it work?

  • Indicate in the publication stage (author journey) of your article that your research was conducted at a Dutch university, a NWO or KNAW research institute, or a university of applied sciences. 
  • Indicate that you opt for a CC-BY license.
  • See the workflow documentation for further explanation.
  • Then choose the Gold Open Access option.

 

Meer informatie

More info on the publisher's website.

More info about the workflow.

 

This contract discloses the “Open Science Platform Products and Services Agreement”.

 

 

You are here

Dutch National website providing information for academics about the advantages of open access to publicly financed research

About this website
 

Contact

Follow us